Navigation Links
PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
Date:6/1/2009

over existing therapeutic approaches for Crohn's disease by potentially offering reduced side effects and convenient oral dosing to patients. Traficet-EN is being developed under a strategic alliance with GlaxoSmithKline's Center of Excellence for External Drug Discovery (CEEDD).

About Crohn's Disease

Crohn's disease is a chronic inflammatory condition of the gastrointestinal tract. It is estimated that the disease affects over 500,000 patients in Europe and North America. Patients suffer periods of flare-ups characterized by intense symptoms, interspersed with periods of relative remission where symptoms decrease or disappear. As Crohn's disease is a chronic condition, patients continue on a given therapeutic regimen from the time of diagnosis over the course of a lifetime, layering additional therapies as flare-ups recur or persist in an effort to reduce symptoms. When medications can no longer control symptoms, patients have few options beyond surgery.

About ChemoCentryx

ChemoCentryx, Inc., is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a network of secreted chemokine molecules, or ligands, and cell surface receptors that regulates inflammation. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has internally generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. ChemoCentryx's lead compound, Traficet-EN, a specific CCR9 antagonist, is in a Phase II/III multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease. CCX025, also a CCR9 antagonist, is in a Phase I clinical trial
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
2. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
3. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
4. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
5. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
6. TNFerade(TM) Phase III Data Presented at ASCO
7. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
8. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
9. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
10. Video: Phase III Study Data With Vandetanib (Zactima(TM)) in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Presented at American Society of Clinical Oncology
11. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Ariz. , Dec. 17, 2014  Beamz ... state-of-the-art interactive music products, today announced that it ... a leading manufacturer and supplier of innovative prosthetic, ... As part of the agreement, RSL Steeper ... bundled solution specifically configured for use within UK ...
(Date:12/17/2014)...  RXi Pharmaceuticals Corporation (NASDAQ: RXII ... and commercializing innovative therapies addressing major unmet medical ... in its first Phase 2a study, RXI-109-1301.  The ... 1-month findings that were reported in September of ... http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , , ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and ... the addition of the "MEMS Gyroscopes Analog ... Analysis" report to their offering. ... gyroscopes for tactical grade applications made a lot ... term of reliability. They are now accepted in ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5MEMS Gyroscopes Analog Devices ADIS16136 Precision Angular Rate Sensor Reverse Costing Analysis 2
... DES MOINES, Iowa, Oct. 16 Protocol ... and announced a partnership,with Hallmark Insights to ... to users of the ConXus health improvement ... and fulfillment services,for reward points earned by ...
... K. Khouri, M.D. a noted Plastic,and Reconstructive Surgeon, ... a,clinical trial performing a minimally invasive breast reconstruction,technique ... grafts primarily on women who have had a ... Typically, breast reconstruction procedures involve major, "open",surgery that ...
Cached Medicine Technology:PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs 2New Minimally Invasive Breast Reconstructive Procedure for Breast Cancer Patients - Actively Recruiting Participants for Clinical Study 2
(Date:12/15/2014)... A recent survey found that the most ... skin health and beauty were: “Connections,” “climate,” “career” and ... and health advocate and radio host Sharon Kleyne agrees ... survey and the Four C’s.* Kleyne notes, however, that ... would benefit from paying attention to one’s daily fresh ...
(Date:12/15/2014)... Veretekk.com, Inc. announced today a strategic alliance ... Ocean Avenue has secured exclusive benefit to the strategic ... JM Ocean Avenue is a direct sales company ... and JM International, with partial ownership coming from JM ... , “After nearly 2 decades of servicing the industry ...
(Date:12/15/2014)... West Palm Beach, FL (PRWEB) December 15, 2014 ... Urgent Care , knows that holidays can be a daze ... accidents. From slips and falls while decking halls, to burns ... are plenty of holiday hazards that can happen at any ... reason for pain, MD Now has made a list of ...
(Date:12/15/2014)... Beltsville, MD (PRWEB) December 15, 2014 ... and services today released “ Social Media Cheat Sheets ... cultivating a community that drives results on the top ... a marketing program. It helps drive awareness, engagement, and ... conversions. For marketers to make an impact on new ...
(Date:12/15/2014)... HealthDay Reporter FRIDAY, Dec. ... reassure the millions of American women who have migraine: The ... "There is no association between migraine and breast cancer risk," ... at Harvard Medical School. "There is no positive association, so ... protective effect either." About 18 percent of American women ...
Breaking Medicine News(10 mins):Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 2Health News:Water and health advocate Sharon Kleyne adds a “W” for fresh water to “four C’s of skin care” 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 2Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 3Health News:JM Ocean Avenue secures the strategic advantages of Veretekk 4Health News:MD Now Urgent Care Presents Healthy Holiday Tips 2Health News:MD Now Urgent Care Presents Healthy Holiday Tips 3Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 2Health News:OutMarket Releases Cheat Sheets for Social Media Marketing 3Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2
... Cancer progression is commonly thought of as a process involving ... which cancer cells leave the primary tumor and spread to ... Cancer Center shows that circulating tumor cells cancer cells ... other areas of the body can also return to ...
... , NEW YORK, Dec. 24 ... the Children,s Health Fund , a ... disadvantaged and medically underserved children, today released the following statement on ... Harry Reid: , "First and foremost, we applaud the Senate ...
... , WASHINGTON, Dec. 24 DNC Chairman Tim Kaine ... the Patient Protection and Affordable Care Act, landmark health care ... after overcoming a series of procedural hurdles and delay tactics ... ever reaching the Senate floor for a vote on final ...
... , WASHINGTON, Dec. 24 The following ... Medical Association: , "Today, the Senate took an historic ... coverage to millions of Americans and strengthening the private insurance ... The AMA supported passage of the bill because it ...
... House plan, before proposal can become law , THURSDAY, Dec. ... a Christmas Eve gift on Thursday with passage of a ... million uninsured Americans. , Obama said the Senate bill contains ... since his inauguration on Jan. 20. "Every single criteria for ...
... ... firms to have attained this highest level , ... (PRWEB) December 24, 2009 -- Partners Consulting’s Managed Services ... CMMI Level 5 Certification, the highest certification level of the Software Engineering Institute (SEI) ...
Cached Medicine News:Health News:'Self-seeding' of cancer cells may play a critical role in tumor progression 2Health News:Children & Health Reform: Where We Stand 2Health News:Children & Health Reform: Where We Stand 3Health News:DNC Chairman Tim Kaine Calls Senate Vote Historic, Says Landmark Health Reform Bill Is a Victory for the American People 2Health News:AMA: Senate Bill Passage Historic, More Work to Do in Conference 2Health News:Senate Passes Health Reform Package 2Health News:Senate Passes Health Reform Package 3Health News:Senate Passes Health Reform Package 4Health News:Partners Consulting's Managed Services Division Achieves CMMI Level 5 Certification 2
... Design for Unparalleled Comfort Pick one of ... balance. Notice the trigger and ejector positionsright where ... our pipettors are ergonomically designed to help avoid ... pipetting. Productivity In The Palm Of Your ...
... best value in high performance electronic pipetting!, ... lightweight design reduce hand fatigue and strain ... tip ejector , Color coding for easy ... for greater performance use Hamilton AdvanTip Low ...
... The Finnpipette BioControl ... innovative features as the ... universal handle fits all ... single channel tip cone ...
... Entire Column of a 384 Well Plate at ... 384 well plates, you need a pipettor that ... exactly what you get with our 16-channel Impact ... Impact/Impact2), this innovation was specifically designed to allow ...
Medicine Products: